The results from Inspire Pharmaceuticals’ second Phase 3 trial of denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis show that the drug failed to meet its primary endpoint, change in FEV from baseline. Denufosol is an ion channel regulator. A previous Phase 3 trial had produced significant change in FEV from baseline, and the company says it will need time to interpret the new data. Read the company’s press release.
